Cryo-Cell gets NYSE American plan acceptance, listing kept through September 9, 2027
Cryo-Cell International received written notice on May 6, 2026 that NYSE Regulation accepted its plan to regain compliance with NYSE American continued listing standards. The company's common stock will keep trading on NYSE American during a plan period ending September 9, 2027, but the company says it cannot assure it will regain compliance by then, and NYSE American may begin delisting proceedings if it does not.
- NYSE Regulation accepted the compliance plan the company submitted on April 8, 2026, and granted a plan period through September 9, 2027.
- The deficiencies cited are a stockholders' deficit as of November 30, 2025, and net losses in two of the three most recent fiscal years.
- Common stock continues to be listed and traded on NYSE American, subject to the plan's initiatives and periodic review.
- If the company fails to regain compliance by the deadline or make progress under the plan, NYSE American may initiate delisting proceedings.